Lindsay Allan Rosenwald
Net Worth

Last updated:

What is Lindsay Allan Rosenwald net worth?

The estimated net worth of Dr. Lindsay Allan Rosenwald is at least $134,041,109 as of 23 Sep 2024. He owns shares worth $117,894,909 as insider and has received compensation worth at least $16,146,200 in Fortress Biotech, Inc. and Fortress Biotech, Inc..

What is the salary of Lindsay Allan Rosenwald?

Dr. Lindsay Allan Rosenwald salary is $576,650 per year as Executive Chairman, Pres & Chief Executive Officer in Fortress Biotech, Inc.. He also receives $576,650 as Executive Chairman, Pres & Chief Executive Officer in Fortress Biotech, Inc..

How old is Lindsay Allan Rosenwald?

Dr. Lindsay Allan Rosenwald is 70 years old, born in 1955.

What stocks does Lindsay Allan Rosenwald currently own?

As insider, Dr. Lindsay Allan Rosenwald owns shares in 2 companies:

Company Title Shares Price per share Total value
Fortress Biotech, Inc. (FBIOP) Executive Chairman, Pres & Chief Executive Officer 15,349,091 $7.57 $116,192,619
Fortress Biotech, Inc. (FBIO) Executive Chairman, Pres & Chief Executive Officer 763,359 $2.23 $1,702,291

What does Fortress Biotech, Inc. do?

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

FBIOP logo
FBIOP
Fortress Biotech, Inc.
$7.57

What does Fortress Biotech, Inc. do?

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

FBIO logo
FBIO
Fortress Biotech, Inc.
$2.23

Lindsay Allan Rosenwald insider trading

Fortress Biotech, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common stock, par value $0.001 763,359 $1.84 $1,404,581
Purchase
Warrants to Purchase Common Stock 763,359 $1.84 $1,404,581
Purchase
SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK 5,000 $7.48 $37,420
Purchase
SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK 5,000 $7.39 $36,970
Purchase
SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK 5,000 $7.35 $36,765
Purchase
COMMON STOCK, PAR VALUE $0.001 20,000 $1.64 $32,720
Purchase
COMMON STOCK, PAR VALUE $0.001 10,000 $1.76 $17,590
Purchase
COMMON STOCK, PAR VALUE $0.001 50,000 $2.38 $118,750
Purchase
Warrants to purchase Common Stock 1,567,515 $1.7 $2,664,776
Purchase
COMMON STOCK, PAR VALUE $0.001 1,567,515 $1.7 $2,664,776
Purchase
COMMON STOCK, PAR VALUE $0.001 100,000 $0.28 $28,300
Purchase
SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK 10,000 $9.34 $93,400
Purchase
SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK 10,000 $11.75 $117,500
Purchase
COMMON STOCK, PAR VALUE $0.001 2,395,209 $0.84 $2,000,000
Purchase
COMMON STOCK, PAR VALUE $0.001 100,000 $0.68 $68,000
Purchase
COMMON STOCK, PAR VALUE $0.001 5,000 $0.56 $2,800
Purchase
COMMON STOCK, PAR VALUE $0.001 100,000 $0.7 $69,500
Purchase
SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK 52,500 $18 $945,000
Purchase
COMMON STOCK, PAR VALUE $0.001 1,123 $2.06 $2,313
Purchase
COMMON STOCK, PAR VALUE $0.001 1,467 $1.1 $1,614
Purchase
SERIES A CUMULATIVE REDEEMABLE PERPETUAL PREFERRED STOCK 40,000 $25 $1,000,000
Purchase
Common Stock, par value $0.001 731 $2.03 $1,484
Purchase
Common Stock, par value $0.001 613 $2.4 $1,471
Purchase
Common Stock, par value $0.001 586 $2.41 $1,412
Purchase
Common Stock, par value $0.001 785 $1.8 $1,413
Purchase
Common Stock, par value $0.001 974 $1.45 $1,412
Purchase
Common Stock, par value $0.001 150,000 $1.61 $241,500
Purchase
Common Stock, par value $0.001 200,000 $5 $1,000,000
Purchase
Common Stock, par value $.001 per share 6,000 $6.95 $41,700
Purchase
Common Stock, par value $.001 per share 2,000 N/A N/A
Purchase
Common Stock, par value $.001 per share 2,000 N/A N/A
Purchase
Common Stock, par value $.001 per share 2,000 $5.66 $11,320
Purchase
Common Stock, par value $0.001 2,000 N/A N/A
Purchase
Common Stock, par value $0.001 2,000 $5.4 $10,800
Purchase
Common Stock, par value $0.001 2,000 $5.49 $10,980
Purchase
Common Stock, par value $0.001 2,000 $5.49 $10,980
Purchase
Common Stock, par value $0.001 2,000 $7 $14,000

Fortress Biotech, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
COMMON STOCK, PAR VALUE $0.001 2,395,209 $0.84 $2,000,000
Purchase
COMMON STOCK, PAR VALUE $0.001 100,000 $0.68 $68,000
Purchase
COMMON STOCK, PAR VALUE $0.001 5,000 $0.56 $2,800
Purchase
COMMON STOCK, PAR VALUE $0.001 100,000 $0.7 $69,500
Purchase
SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK 52,500 $18 $945,000
Purchase
COMMON STOCK, PAR VALUE $0.001 1,123 $2.06 $2,313
Purchase
COMMON STOCK, PAR VALUE $0.001 1,467 $1.1 $1,614
Purchase
SERIES A CUMULATIVE REDEEMABLE PERPETUAL PREFERRED STOCK 40,000 $25 $1,000,000
Purchase
Common Stock, par value $0.001 731 $2.03 $1,484
Purchase
Common Stock, par value $0.001 613 $2.4 $1,471
Purchase
Common Stock, par value $0.001 586 $2.41 $1,412
Purchase
Common Stock, par value $0.001 785 $1.8 $1,413
Purchase
Common Stock, par value $0.001 974 $1.45 $1,412
Purchase
Common Stock, par value $0.001 150,000 $1.61 $241,500
Purchase
Common Stock, par value $0.001 200,000 $5 $1,000,000
Purchase
Common Stock, par value $.001 per share 6,000 $6.95 $41,700
Purchase
Common Stock, par value $.001 per share 2,000 $5.66 $11,320
Purchase
Common Stock, par value $.001 per share 2,000 $5.67 $11,340
Purchase
Common Stock, par value $.001 per share 2,000 $5.66 $11,320
Purchase
Common Stock, par value $0.001 2,000 $5.4 $10,800
Purchase
Common Stock, par value $0.001 2,000 $5.4 $10,800
Purchase
Common Stock, par value $0.001 2,000 $5.49 $10,980
Purchase
Common Stock, par value $0.001 2,000 $5.49 $10,980
Purchase
Common Stock, par value $0.001 2,000 $7 $14,000

Fortress Biotech key executives

Fortress Biotech, Inc. executives and other stock owners filed with the SEC: